Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nutra Pharma has expanded its licensing agreement with NanoLogix, to include intellectual property for the use of testing the environment for nontuberculous mycobacterium.
Subscribe to our email newsletter
Nutra Pharma’s wholly-owned medical devices subsidiary, Designer Diagnostics, is currently planning to undergo third party validation for its nontuberculous mycobacterium (NTM) diagnostic test kits at Tuberculosis Research Institute, National Jewish Medical and Research Center, in Denver, Colorado. The company plans to apply for FDA approval upon successful completion of this clinical trial.
Rik Deitsch, chairman and CEO of Nutra Pharma, said: “Combining our newly licensed intellectual property with our current test kit technology will allow our subsidiary, Designer Diagnostics, to attempt to successfully launch a cost-effective solution to help identify the environmental sources of NTM infections.”